Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heat therapy gives new hope for advanced pancreatic cancer patients

NCT ID NCT07191418

Disease control Sponsor: Roberto Valente Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 25, 2026 · Updated 2 times

Summary

This study tests whether adding a heat-based treatment called radiofrequency ablation (RFA) to a standard procedure (ERCP) can help people with advanced pancreatic cancer that has spread to the liver live longer. About 178 adults with limited liver spread will be randomly assigned to get either the standard ERCP alone or ERCP plus RFA. The goal is to see if the added heat treatment improves cancer-specific survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 178 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Individuals with newly diagnosed pancreatic cancer in the head of the pancreas causing compression on the bile duct. * Metastatic stage to the liver * Histologically or cytologically confirmed mPDAC. * Cancer burden limited to maximum 5 metastases in the liver, each of them maximum 1 cm in the larger diameter. * Patients must be under palliative chemotherapy treatment. * Cancer should be radiologically measurable (in an area not previously irradiated). * WHO performance status 0-2. * Age 18-85 years. Exclusion Criteria: * Intellectual disability, unwillingness or language difficulties * which hinders the ability to give informed consent. * Ongoing extensive immunosuppression and/or severe leuko- or * thrombocytopenia. * Ongoing acute cholangitis. * Ongoing sepsis. * Acute kidney failure. * Uncompensated heart failure or unstable coronary insufficiency * (symptomatic/uncompensated). * Pregnancy or breastfeeding. * Any metastases outside the liver. * Cardiac pacemakers/cardioverter defibrillators. * Severe coagulopathy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic pancreatic ductal adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pancreatic cancer metastatic to liver

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Surgery, Umeå University Hospital

    RECRUITING

    Umeå, 90185, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.